Evidence map›Paper›PMID 40969272›Full record

ArticleFrontiers in oncology2025

Prognostic significance of FDG-PET/CT based radiomics analysis in newly-diagnosed multiple myeloma: a comparative study with clinical assessment.

Fei Li, Baiyang Jiang, Ye Fu, Qingyang Yu, Guangwen Duan, Jiayang Yan, Qinling Jiang, Hongbiao Sun, Yi Xiao, Qi Chen and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Fei Li *Department of Research and Development, Shanghai United Imaging Intelligence Co., Ltd., Shanghai, China.
Baiyang Jiang *Department of Radiology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Ye Fu *Department of Radiology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Qingyang YuDepartment of Radiology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Guangwen DuanDepartment of Radiology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Jiayang YanDepartment of Radiology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Qinling JiangDepartment of Radiology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Hongbiao SunDepartment of Radiology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Yi XiaoDepartment of Radiology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Qi ChenDepartment of Radiology, Kunshan Third People's Hospital, Kunshan, Jiangsu, China.
Shaochun XuDepartment of Radiology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Xiang WangDepartment of Radiology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Shiyuan LiuDepartment of Radiology, Changzheng Hospital, Naval Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to construct and validate a fusion diagnostic model based on Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography(FDG-PET/CT) radiomics for predicting overall survival of multiple myeloma (MM) patients. Methods: A total of 199 patients newly diagnosed with MM were included from two centers. All patients underwent whole-body PET Results: The C-indexes for the radiomics model in the training and testing cohorts were 0.736 and 0.708, respectively; for the clinical model, they were 0.676 and 0.696, respectively; and for the integrated model, they were 0.791 and 0.776, respectively. The integrated diagnostic model outperformed both the radiomics and clinical models, showcasing higher discriminative ability and improved calibration. In the training set, the C-index was 0.791 (95% confidence interval [CI]: 0.713-0.853), with an ICI of 0.015, E50 of 0.014, and AIC of 10.987. In the testing set, the C-index was 0.776 (95% CI: 0.654-0.894), with an ICI of 0.069, E50 of 0.04, and AIC of 11.492. Conclusions: This integrated prediction model exhibited satisfactory performance in predicting survival outcomes for patients diagnosed with MM and improved precision in discriminating between patients with a good prognosis and poor prognosis.

Indexed as

18-FDG PET/CTcomputer-aided diagnosismultiple myelomaprognostic valueradiomics

Identifiers

PMID40969272
PMCPMC12441919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.